Shark novel antigen receptors

the next generation of biologic therapeutics?

Caroline Barelle, Davinder S. Gill, Keith Charlton

Research output: Chapter in Book/Report/Conference proceedingChapter

20 Citations (Scopus)

Abstract

Over recent decades we have witnessed a revolution in health care as new classes of therapeutics based on natural biological molecules have become available to medical practitioners. These promised to target some of the most serious conditions that had previously evaded traditional small molecule drugs, such as cancers and to alleviate many of the concerns of patients and doctors alike regarding adverse side effects and impaired quality of life that are often associated with chemo-therapeutics. Many early 'biologics' were based on antibodies, Nature's answer to invading pathogens and malignancies, derived from rodents and in many ways failed to live up to expectations. Most of these issues were subsequently negated by technological advances that saw the introduction of human or "humanized' antibodies and have resulted in a number of commercial 'block-busters'. Today, most of the large pharmaceutical companies have product pipelines that include an increasing proportion of biologic as opposed to small molecule compounds. The limitations of antibodies or other large protein drugs are now being realized however and ever more inventive solutions are being sought to develop equally efficacious but smaller, more soluble, more stable and less costly alternatives to broaden the range of drug-able targets and therapeutic options. The aim of this chapter is to introduce the reader to one such novel approach that seeks to exploit a unique antibody-like protein evolved by ancestral sharks over 450 M years ago and that may lead to a host of new therapeutic opportunities and help us to tackle some of the pressing clinical demands of the 21 st century.
Original languageEnglish
Title of host publicationPharmaceutical Biotechnology
EditorsCarlos A. Guzman, Giora Z. Feuerstein
Place of PublicationNew York
PublisherSpringer
Pages49-62
Number of pages14
Volume655
ISBN (Electronic)978-1-4419-1132-2
ISBN (Print)978-1-4419-1131-5
DOIs
Publication statusPublished - 20 Oct 2009

Publication series

NameAdvances in Experimental Medicine and Biology
PublisherSpringer
Volume655
ISSN (Print)0065-2598

Fingerprint

Sharks
Antigen Receptors
Pharmaceutical Preparations
Antibodies
Antibodies, Monoclonal, Humanized
Therapeutics
Biological Products
Rodentia
Neoplasms
Proteins
Quality of Life
Delivery of Health Care

Keywords

  • animals
  • antibodies
  • antigens
  • biological agents
  • chemistry, pharmaceutical
  • disulfides
  • dogfish
  • drug design
  • humans
  • immunoglobulins
  • protein conformation
  • protein structure, tertiary
  • sharks
  • technology, pharmaceutical

Cite this

Barelle, C., Gill, D. S., & Charlton, K. (2009). Shark novel antigen receptors: the next generation of biologic therapeutics? In C. A. Guzman, & G. Z. Feuerstein (Eds.), Pharmaceutical Biotechnology (Vol. 655, pp. 49-62). (Advances in Experimental Medicine and Biology; Vol. 655). New York: Springer . https://doi.org/10.1007/978-1-4419-1132-2_6

Shark novel antigen receptors : the next generation of biologic therapeutics? / Barelle, Caroline; Gill, Davinder S.; Charlton, Keith.

Pharmaceutical Biotechnology. ed. / Carlos A. Guzman; Giora Z. Feuerstein. Vol. 655 New York : Springer , 2009. p. 49-62 (Advances in Experimental Medicine and Biology; Vol. 655).

Research output: Chapter in Book/Report/Conference proceedingChapter

Barelle, C, Gill, DS & Charlton, K 2009, Shark novel antigen receptors: the next generation of biologic therapeutics? in CA Guzman & GZ Feuerstein (eds), Pharmaceutical Biotechnology. vol. 655, Advances in Experimental Medicine and Biology, vol. 655, Springer , New York, pp. 49-62. https://doi.org/10.1007/978-1-4419-1132-2_6
Barelle C, Gill DS, Charlton K. Shark novel antigen receptors: the next generation of biologic therapeutics? In Guzman CA, Feuerstein GZ, editors, Pharmaceutical Biotechnology. Vol. 655. New York: Springer . 2009. p. 49-62. (Advances in Experimental Medicine and Biology). https://doi.org/10.1007/978-1-4419-1132-2_6
Barelle, Caroline ; Gill, Davinder S. ; Charlton, Keith. / Shark novel antigen receptors : the next generation of biologic therapeutics?. Pharmaceutical Biotechnology. editor / Carlos A. Guzman ; Giora Z. Feuerstein. Vol. 655 New York : Springer , 2009. pp. 49-62 (Advances in Experimental Medicine and Biology).
@inbook{3462798f40584627818438a7a1a9d5c9,
title = "Shark novel antigen receptors: the next generation of biologic therapeutics?",
abstract = "Over recent decades we have witnessed a revolution in health care as new classes of therapeutics based on natural biological molecules have become available to medical practitioners. These promised to target some of the most serious conditions that had previously evaded traditional small molecule drugs, such as cancers and to alleviate many of the concerns of patients and doctors alike regarding adverse side effects and impaired quality of life that are often associated with chemo-therapeutics. Many early 'biologics' were based on antibodies, Nature's answer to invading pathogens and malignancies, derived from rodents and in many ways failed to live up to expectations. Most of these issues were subsequently negated by technological advances that saw the introduction of human or {"}humanized' antibodies and have resulted in a number of commercial 'block-busters'. Today, most of the large pharmaceutical companies have product pipelines that include an increasing proportion of biologic as opposed to small molecule compounds. The limitations of antibodies or other large protein drugs are now being realized however and ever more inventive solutions are being sought to develop equally efficacious but smaller, more soluble, more stable and less costly alternatives to broaden the range of drug-able targets and therapeutic options. The aim of this chapter is to introduce the reader to one such novel approach that seeks to exploit a unique antibody-like protein evolved by ancestral sharks over 450 M years ago and that may lead to a host of new therapeutic opportunities and help us to tackle some of the pressing clinical demands of the 21 st century.",
keywords = "animals, antibodies, antigens, biological agents, chemistry, pharmaceutical, disulfides, dogfish, drug design, humans, immunoglobulins, protein conformation, protein structure, tertiary, sharks, technology, pharmaceutical",
author = "Caroline Barelle and Gill, {Davinder S.} and Keith Charlton",
year = "2009",
month = "10",
day = "20",
doi = "10.1007/978-1-4419-1132-2_6",
language = "English",
isbn = "978-1-4419-1131-5",
volume = "655",
series = "Advances in Experimental Medicine and Biology",
publisher = "Springer",
pages = "49--62",
editor = "Guzman, {Carlos A.} and Feuerstein, {Giora Z.}",
booktitle = "Pharmaceutical Biotechnology",

}

TY - CHAP

T1 - Shark novel antigen receptors

T2 - the next generation of biologic therapeutics?

AU - Barelle, Caroline

AU - Gill, Davinder S.

AU - Charlton, Keith

PY - 2009/10/20

Y1 - 2009/10/20

N2 - Over recent decades we have witnessed a revolution in health care as new classes of therapeutics based on natural biological molecules have become available to medical practitioners. These promised to target some of the most serious conditions that had previously evaded traditional small molecule drugs, such as cancers and to alleviate many of the concerns of patients and doctors alike regarding adverse side effects and impaired quality of life that are often associated with chemo-therapeutics. Many early 'biologics' were based on antibodies, Nature's answer to invading pathogens and malignancies, derived from rodents and in many ways failed to live up to expectations. Most of these issues were subsequently negated by technological advances that saw the introduction of human or "humanized' antibodies and have resulted in a number of commercial 'block-busters'. Today, most of the large pharmaceutical companies have product pipelines that include an increasing proportion of biologic as opposed to small molecule compounds. The limitations of antibodies or other large protein drugs are now being realized however and ever more inventive solutions are being sought to develop equally efficacious but smaller, more soluble, more stable and less costly alternatives to broaden the range of drug-able targets and therapeutic options. The aim of this chapter is to introduce the reader to one such novel approach that seeks to exploit a unique antibody-like protein evolved by ancestral sharks over 450 M years ago and that may lead to a host of new therapeutic opportunities and help us to tackle some of the pressing clinical demands of the 21 st century.

AB - Over recent decades we have witnessed a revolution in health care as new classes of therapeutics based on natural biological molecules have become available to medical practitioners. These promised to target some of the most serious conditions that had previously evaded traditional small molecule drugs, such as cancers and to alleviate many of the concerns of patients and doctors alike regarding adverse side effects and impaired quality of life that are often associated with chemo-therapeutics. Many early 'biologics' were based on antibodies, Nature's answer to invading pathogens and malignancies, derived from rodents and in many ways failed to live up to expectations. Most of these issues were subsequently negated by technological advances that saw the introduction of human or "humanized' antibodies and have resulted in a number of commercial 'block-busters'. Today, most of the large pharmaceutical companies have product pipelines that include an increasing proportion of biologic as opposed to small molecule compounds. The limitations of antibodies or other large protein drugs are now being realized however and ever more inventive solutions are being sought to develop equally efficacious but smaller, more soluble, more stable and less costly alternatives to broaden the range of drug-able targets and therapeutic options. The aim of this chapter is to introduce the reader to one such novel approach that seeks to exploit a unique antibody-like protein evolved by ancestral sharks over 450 M years ago and that may lead to a host of new therapeutic opportunities and help us to tackle some of the pressing clinical demands of the 21 st century.

KW - animals

KW - antibodies

KW - antigens

KW - biological agents

KW - chemistry, pharmaceutical

KW - disulfides

KW - dogfish

KW - drug design

KW - humans

KW - immunoglobulins

KW - protein conformation

KW - protein structure, tertiary

KW - sharks

KW - technology, pharmaceutical

U2 - 10.1007/978-1-4419-1132-2_6

DO - 10.1007/978-1-4419-1132-2_6

M3 - Chapter

SN - 978-1-4419-1131-5

VL - 655

T3 - Advances in Experimental Medicine and Biology

SP - 49

EP - 62

BT - Pharmaceutical Biotechnology

A2 - Guzman, Carlos A.

A2 - Feuerstein, Giora Z.

PB - Springer

CY - New York

ER -